Ablynx Information

View Top Employees from Ablynx

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.

Website	https://www.ablynx.com
Revenue	$138.5 million
Funding	$227.6 million
Employees	115 (82 on RocketReach)
Founded	2001
Address	21 Technologiepark Zwijnaarde, Gent, Flanders 9052, BE
Phone	+32 9 262 00 00
Fax	(329) 262-0001
Technologies	JavaScript , HTML , Twitter +48 more (view full list)
Industry	Biotechnology Research, Business Services General, Discovery, Business Services, Research and Drug Development
Keywords	Therapeutic Proteins, Biotechnology, Pharmaceutical, Drug Development, Protein Engineering, Immunology, Biopharma, Therapeutics, Small Molecule Drugs, Monoclonal Antibodies, Biologics, Drug Discovery, Clinical Trials, Research And Development, Life Sciences, Healthcare, Molecular Biology
Competitors	Roche, Novartis, AbbVie, Merck & Co., Inc., Sanofi, Bristol Myers Squibb, Genentech, Amgen, Gilead Sciences, Biogen +41 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 283 Companies, SIC Code 873 Companies, SIC Code 28 Companies
NAICS	NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies